Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease
LS Mean VAS Low Back Pain Change from Baseline VAS of 60.4 – Entire Study…
Digital Heroes Marks 2,000 Brand Launches Across 55 Countries Through Global Technology Services
ANT Law Firm Strengthens Its Orlando Legal Services for Car Accident, Slip and Fall, and Wrongful Death Victims
LumenIsle Launches Australian Market Service Review and International Video Traceability Initiative for Memorial Diamonds
HiBob Named Best HR Management Software in the UK for 2026
Ionik Announces 30-Day Extension of Senior Debt Facility